Quiero saber acerca de...

Federal Register / Vol. 86, No. 26 / Wednesday, February 10, 2021 / Notices certain information to assure the dutyfree entry of the supplies.
e. Construction provisions and clauses:
52.2259, Buy American Construction Materials 52.22510, Notice of Buy American RequirementConstruction Materials 52.22511, Buy AmericanConstruction Materials Under Trade Agreements 52.22512, Notice of Buy American RequirementConstruction Materials under Trade Agreements 52.22521, Required Use of American Iron, Steel and Manufactured Goods Buy AmericanConstruction Materials 52.22523, Required Use of American Iron, Steel and Manufactured Goods Buy AmericanConstruction Materials Under Trade Agreements The listed provisions and clauses provide that an offeror or contractor requesting to use foreign construction material due to unreasonable cost of domestic construction material shall provide adequate information to permit evaluation of the request.
C. Annual Burden Respondents: 8,771.
Total Annual Responses: 43,891.
Total Burden Hours: 40,738.
D. Public Comment A 60-day notice was published in the Federal Register at 85 FR 63276, on October 7, 2020. No comments were received.
Obtaining Copies: Requesters may obtain a copy of the information collection documents from the GSA
Regulatory Secretariat Division, by calling 2025014755 or emailing GSARegSec@gsa.gov. Please cite OMB
Control No. 90000024, Buy American, Trade Agreements, and Duty-Free Entry.
Janet Fry, Director, Federal Acquisition Policy Division, Office of Governmentwide Acquisition Policy, Office of Acquisition Policy, Office of Governmentwide Policy.
FR Doc. 202102689 Filed 2921; 8:45 am BILLING CODE 6820EPP

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and Prevention Notice of Closed Meeting Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

VerDate Sep<11>2014

18:53 Feb 09, 2021

Jkt 253001

The meeting will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel SEP
Panel 1, Panel 2, and Panel 3: GH21
003, Advancing Public Health Research in Kenya; GH21004, Conducting Research to Inform Pandemic Response and Recovery of Emergency-Affected Populations by Determining Public Health Needs, Improving Methods, and Integrating Services to Mitigate Morbidity and Mortality; and GH21
006, Strengthening Public Health Research and Implementation Science Operations Research to Control and Eliminate Infectious Diseases Globally.
Dates: March 3031, 2021 and April 1, 2021.
Time: 9:00 a.m.2:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant applications.
For Further Information Contact:
Hylan Shoob, Ph.D., Scientific Review Officer, Center for Global Health, CDC, 1600 Clifton Drive, Atlanta, Georgia 303294027, Telephone 404 6394796, HShoob@cdc.gov.
The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.
FR Doc. 202102738 Filed 2921; 8:45 am BILLING CODE 416318P

PO 00000

Frm 00034

Fmt 4703

Sfmt 4703

8915

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel SEPDP21002, Epidemiologic Cohort Study of Interstitial Cystitis; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel SEPDP21
002, Epidemiologic Cohort Study of Interstitial Cystitis, March 30, 2021, 10:00 a.m.6:00 p.m., EST, which was published in the Federal Register on Friday, December 11, 2020, Volume 85, Number 239, page 80107.
The meeting on March 30, 2021 is being amended to change the time and should read as follows:
Time: 12:00 p.m.3:00 p.m., EDT.
The meeting is closed to the public.
For Further Information Contact: Jaya Raman, Ph.D., Scientific Review Officer, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, Mailstop S1078, Atlanta, Georgia 30341, Telephone 770
4886511, JRaman@cdc.gov.
The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.
FR Doc. 202102736 Filed 2921; 8:45 am BILLING CODE 416318P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and Prevention Notice of Closed Meeting Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, Title 5 U.S.C.,
E:FRFM10FEN1.SGM

10FEN1